| James C Oates, MD | |
|
2125 Charlie Hall Blvd, Charleston, SC 29414-5879 | |
| (843) 573-1500 | |
| (843) 573-1535 |
| Full Name | James C Oates |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 33 Years |
| Location | 2125 Charlie Hall Blvd, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831207885 | NPI | - | NPPES |
| 188362 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 18836 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Musc Medical Center | Charleston, SC | Hospital |
| Beaufort County Memorial Hospital | Beaufort, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Medical Associates Of The Medical University Of South Carol | 6305758574 | 1297 |
News Archive
Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.
For the first time, a variant in UBQLN4 gene has been associated with Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS) - a progressive disease resulting in the loss of nerve cells that control muscle movement, which eventually leads to paralysis and death.
A study of over 87,000 documents obtained through Freedom of Information requests has revealed a contract mechanism that could allow Coca-Cola to "quash" findings from some of the health research it funds at public universities in the US and Canada.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
› Verified 1 days ago
| Entity Name | University Medical Associates Of The Medical University Of South Carol |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043241110 PECOS PAC ID: 6305758574 Enrollment ID: O20031105000291 |
News Archive
Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.
For the first time, a variant in UBQLN4 gene has been associated with Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS) - a progressive disease resulting in the loss of nerve cells that control muscle movement, which eventually leads to paralysis and death.
A study of over 87,000 documents obtained through Freedom of Information requests has revealed a contract mechanism that could allow Coca-Cola to "quash" findings from some of the health research it funds at public universities in the US and Canada.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James C Oates, MD Po Box 751461, Charlotte, NC 28275-1461 Ph: (843) 792-6200 | James C Oates, MD 2125 Charlie Hall Blvd, Charleston, SC 29414-5879 Ph: (843) 573-1500 |
News Archive
Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.
For the first time, a variant in UBQLN4 gene has been associated with Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS) - a progressive disease resulting in the loss of nerve cells that control muscle movement, which eventually leads to paralysis and death.
A study of over 87,000 documents obtained through Freedom of Information requests has revealed a contract mechanism that could allow Coca-Cola to "quash" findings from some of the health research it funds at public universities in the US and Canada.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
› Verified 1 days ago
Dr. Jeffrey Peter Yourshaw, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 169 Ashley Ave, Room 202 Main Hospital Msc 333, Charleston, SC 29425 Phone: 843-876-4807 Fax: 843-876-4809 | |
Jennifer Lee Martin, D.O. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Nikko Rowe Asuncion Tabliago, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Charleston, SC 29425 Phone: 843-792-2575 | |
Moses K Asempah, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 169 Ashley Avenue, Room 202 Main Hospital Msc333, Charleston, SC 29425 Phone: 717-491-3745 | |
Paige Nicole Laverick, PA-C Rheumatology Medicare: Medicare Enrolled Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Amit Agrawal, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Yevgeniy Gelfand, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 67 President St, Charleston, SC 29425 Phone: 843-792-0111 |